Filing seeks to extend EL-22 myostatin-engineered probiotic platform into pharmaceutical applications for muscle preservation ...
Investors had every reason to suspect today's news from Sagimet Biosciences (SGMT +48.46%) was coming sooner or later.
Juniper Biosciences today announced a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of JBS-003 (18F-fluoromisonidazole, or FMISO). This ...
Filing seeks to extend EL-22 myostatin-engineered probiotic platform into pharmaceutical applications for muscle preservation in patients on ...
Precision BioSciences, Inc. (DTIL) 25th Annual Needham Virtual Healthcare Conference April 14, 2026 9:30 AM EDTCompany ParticipantsJohn Kelly - CFO ...
AUSTIN, Texas, March 30, 2026 /PRNewswire/ -- The Texas Healthcare & Bioscience Institute (THBI), the statewide public policy voice of the healthcare and bioscience industry, today released a ...
French biotech firm One Biosciences, which uses artificial intelligence to develop personalized cancer treatments, is setting ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
By Arasu Kannagi Basil and Prakhar Srivastava April 17 (Reuters) - Alamar Biosciences fetched a $1.53 billion valuation after ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the ...
Pulse Biosciences is positioning its nanosecond PFA technology as a game-changer in the competitive atrial fibrillation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results